The value of laboratory medicine in prevention

AUTORI

ABSTRACT

Screening is generally defined as an intervention aimed at identifying individuals with apparently good health, who may be at higher risk of developing health problems or diseases, so that early clinical management could be offered. Screening is also one of the most important aspects of laboratory medicine, but the use of laboratory tests for preventing diseases is often overlooked unless it is officially endorsed or supported by the governments. However, as briefly summarized in this opinion paper, some commonly used and relatively inexpensive tests have been shown to provide significant clinical and even economic benefits, increasing the value of laboratory testing beyond the detection of disease in frankly symptomatic people. Early identification of individuals at increased risk of developing cardiovascular disease by low-density lipoprotein (LDL) cholesterol, heart failure by natriuretic peptides, diabetes by HbA1c, Alzheimer’s disease by cerebrospinal fluid biomarkers, along with early multicancer detection through cell-free DNA, represents only a small part of the value of laboratory medicine in prevention, but reveals its enormous potential for the future. We should all start thinking outside the box, because if we spend a little more on laboratory testing now, we could obtain significant savings in the healthcare system afterwards.

BIBLIOGRAFIA

1. World Health Organization. Screening programs: a short guide. Increase effectiveness, maximize benefits and minimize harm. Copenhagen: WHO Regional Office for Europe; 2020. Licence: CC BY-NC-SA 3.0 IGO.
2. Istituto Superiore di Sanità. Criteri per lo screening di popolazione. https://www.iss.it/d1ce-criteri-per-lo-screening. (last accessed: June 2024)
3. Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: World Health Organization; 1968.
4. Weinstein MC. The costs of prevention. J Gen Intern Med 1990;5:S89-92.
5. Cohen DJ, Reynolds MR. Interpreting the results of cost-effectiveness studies. J Am Coll Cardiol 2008;52:2119-26.
6. Lippi G, Plebani M. A modern and pragmatic definition of Laboratory Medicine. Clin Chem Lab Med 2020;58:1171.
7. Hallworth MJ. The ‘70% claim’: what is the evidence base? Ann Clin Biochem 2011;48:487-8.
8. Lippi G. The irreplaceable value of laboratory diagnostics: four recent tests that have revolutionized clinical practice. EJIFCC 2019;30:7-13.
9. Rohr UP, Binder C, Dieterle T, Giusti F, Messina CG, Toerien E, et al. The value of in vitro diagnostic testing in medical practice: a status report. PLoS One 2016;11:e0149856.
10. Lippi G, Plebani M. The add value of laboratory diagnostics: the many reasons why decision-makers should actually care. J Lab Prec Med 2017;2:100.
11. Hernandez JS. Cost-effectiveness of laboratory testing. Arch Pathol Lab Med 2003;127:440-5.
12. Hu J, Zhang Z, Shen WJ, Azhar S. Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones. Nutr Metab (Lond) 2010;7:47.
13. Helkin A, Stein JJ, Lin S, Siddiqui S, Maier KG, Gahtan V. Dyslipidemia Part 1 -Review of lipid metabolism and vascular cell physiology. Vasc Endovascular Surg 2016;50:107-18.
14. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation 1998;97:1876-87.
15. Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol 2011;8:502-12.
16. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;140:e596-646.
17. Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019;290:140-205
18. Istituto Superiore di Sanità. Colesterolo (analisi cliniche). Available at: https://www.issalute.it/index.php/la-salute-dalla-a-alla-z-menu/c/colesterolo-analisi-cliniche. (Last accessed: June 2024).
19. Guirguis-Blake JM, Evans CV, Coppola EL, Redmond N, Perdue LA. Screening for lipid disorders in children and adolescents: updated evidence report and systematic review for the US preventive services task force. JAMA 2023;330:261-74.
20. Wu F, Jacobs DR Jr, Daniels SR, Kähönen M, Woo JG, Sinaiko AR, et al. Non-high-density lipoprotein cholesterol levels from childhood to adulthood and cardiovascular disease events. JAMA. 2024. doi: 10.1001/jama.2024.4819. (ahead of print).
21. Kohli-Lynch CN, Bellows BK, Thanassoulis G, Zhang Y, Pletcher MJ, Vittinghoff E, et al. Cost-effectiveness of Low-density Lipoprotein Cholesterol level-guided statin treatment in patients with borderline cardiovascular risk. JAMA Cardiol 2019;4:969-77.
22. Kohli-Lynch CN, Bellows BK, Zhang Y, Spring B, Kazi DS, Pletcher MJ, et al. Cost-effectiveness of lipid-lowering treatments in young adults. J Am Coll Cardiol 2021;78:1954-64.
23. Oremus M, McKelvie R, Don-Wauchope A, Santaguida PL, Ali U, Balion C, et al. A systematic review of BNP and NT-proBNP in the management of heart failure: overview and methods. Heart Fail Rev 2014;19:413-9.
24. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4-131.
25. Jafari A, Rezapour A, Hajahmadi M. Cost-effectiveness of B-type natriuretic peptide-guided care in patients with heart failure: a systematic review. Heart Fail Rev 2018;23:693-700.
26. American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: standards of care in diabetes-2024. Diabetes Care 2024;47:S20-42.
27. Diabetes Prevention Program Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care 2015;38:51-8.
28. Ohde S, Moriwaki K, Takahashi O. Cost-effectiveness analysis for HbA1c test intervals to screen patients with type 2 diabetes based on risk stratification. BMC Endocr Disord 2021;21:105.
29. Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 2009;11:111-28.
30. Skaria AP. The economic and societal burden of Alzheimer disease: managed care considerations. Am J Manag Care 2022;28:S188-96.
31. Jia J, Ning Y, Chen M, Wang S, Yang H, Li F, et al. Biomarker changes during 20 years preceding Alzheimer’s disease. N Engl J Med 2024;390:712-22.
32. McRae I, Zheng L, Bourke S, Cherbuin N, Anstey KJ. Cost-Effectiveness of dementia prevention interventions. J Prev Alzheimers Dis 2021;8:210-7.
33. Schrag D, Beer TM, McDonnell CH 3rd, Nadauld L, Dilaveri CA, Reid R, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet 2023;402:1251-60.
34. Connal S, Cameron JM, Sala A, Brennan PM, Palmer DS, Palmer JD, et al. Liquid biopsies: the future of cancer early detection. J Transl Med 2023;21:118.
35. Lippi G, Mattiuzzi C. COVID-19: Imparare dal passato. Biochim Clin 2023;47:1-3.
36. Plebani M, Laposata M, Lippi G. A manifesto for the future of laboratory medicine professionals. Clin Chim Acta 2019;489:49-52.
37. Lippi G. A manifesto for the future of laboratory medicine: what remains to be done? Biochim Clin 2023;47 Suppl 2: 74-78.